Efficacy and safety of simenafil in erectile dysfunction: a phase II, randomized, double-blind, placebo-controlled, crossover study
Asian Journal of Andrology · 2026-11 · 28 (6) · 914-918
DOI: 10.4103/aja202622 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Asian Journal of Andrology, online erschienen am 11.09.2026. Verfasst von Zhe Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Center for Reproductive Medicine, Peking University Third Hospital, Beijing 100191, China. Hauptthemen laut MEDLINE: Erectile Dysfunction, Phosphodiesterase 5 Inhibitors, Pyrimidines. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Simenafil, a newly developed oral phosphodiesterase type 5 (PDE5) inhibitor, substantially improves erectile function; however, its efficacy has not been evaluated via RigiScan monitoring. This study evaluated the efficacy and safety of simenafil in erectile dysfunction (ED) using audiovisual sexual stimulation. A randomized, double-blind, placebo-controlled, multicenter, two-cohort, three-way crossover study was conducted in 84 men aged 18–65 years with mild-to-moderate ED of ≥6 months. Each patient received placebo, simenafil 5.0 mg, and simenafil 2.5 mg (Cohort A, n = 42) or 10.0 mg (Cohort B, n = 42) administered in random order at least 5 days apart. RigiScan was used to assess the time to achieve and duration of ≥60% penile rigidity. In Cohort A, relative to placebo, 2.5 mg simenafil (single-dose) led to a least square mean (LSM) increase in the duration of ≥60% penile rigidity of 3.1 min (95% confidence interval [CI]: 0.5–5.7 min, P = 0.021) and 8.3 min (95% CI: 3.5–13.2 min, P = 0.001) at the tip and base, respectively; for the 5.0 mg, it was 3.7 min (95% CI: 1.0–6.4 min, P = 0.008) and 8.5 min (95% CI: 3.5–13.5 min, P = 0.001) at the tip and base, respectively. In Cohort B, the LSM duration of ≥60% rigidity of the penile base was significantly longer with 10.0 mg simenafil than with placebo by 5.9 min (95% CI: 0.8–10.9 min, P = 0.023). The 5.0 mg (tip and base) and 10.0 mg (tip) simenafil were not statistically significant compared with the placebo (all P > 0.05). The pharmacodynamic and safety profiles support simenafil as a suitable candidate for further investigation in ED.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Center for Reproductive Medicine, Peking University Third Hospital, Beijing 100191, China.
- Department of Andrology and Sexual Medicine, Institute of Sexual Medicine, The Second Hospital of Dalian Medical University, Dalian 116023, China.
- Department of Andrology, Nanjing Drum Tower Hospital, Nanjing 21008, China.
- Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022, China.
- Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou 215006, China.
- Department of Urology and Andrology, Henan Provincial People's Hospital, Zhengzhou 450003, China.
Zitieren
APA
Zhang, Z., Jiang, T., Dai, Y. T., Zhang, X. S., Huang, Y. H., Zhang, X. S., Zhou, H. L., Juan, J. X., Duan, H. Q., & Jiang, H. (2026). Efficacy and safety of simenafil in erectile dysfunction: a phase II, randomized, double-blind, placebo-controlled, crossover study. Asian Journal of Andrology, 28(6), 914-918. https://doi.org/10.4103/aja202622
Vancouver
Zhang Z, Jiang T, Dai YT, Zhang XS, Huang YH, Zhang XS, et al. Efficacy and safety of simenafil in erectile dysfunction: a phase II, randomized, double-blind, placebo-controlled, crossover study. Asian Journal of Andrology. 2026;28(6):914-918. doi:10.4103/aja202622
BibTeX
@article{Zhang2026,
author = {Zhang, Zhe and Jiang, Tao and Dai, Yu-Tian and Zhang, Xian-Sheng and Huang, Yu-Hua and Zhang, Xiang-Sheng and Zhou, Hui-Liang and Juan, Jia-Xiang and Duan, Hua-Qing and Jiang, Hui},
title = {Efficacy and safety of simenafil in erectile dysfunction: a phase II, randomized, double-blind, placebo-controlled, crossover study},
journal = {Asian Journal of Andrology},
year = {2026},
volume = {28},
number = {6},
pages = {914--918},
doi = {10.4103/aja202622}
}
EUVIMED